Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8658204 | 0.98 | MAPK1 (0.62) | MAPK1KDM4EGAAL3MBTL1MAPT | |
| SCHEMBL8439255 | 0.82 | KDM4E (0.70) | MAPK1KDM4EGAAL3MBTL1MAPT | |
| SCHEMBL12233268 | 0.82 | MAPK1 (0.53) | MAPK1KDM4EMAPTALDH1A1RECQL | |
| SCHEMBL28775271 | 0.80 | KDM4E (0.53) | MAPK1KDM4EGAAL3MBTL1MAPT | |
| SCHEMBL6876786 | 0.79 | GAA (0.58) | MAPK1KDM4EGAAL3MBTL1ALDH1A1 | |
| SCHEMBL18989534 | 0.79 | ALDH1A1 (0.46) | MAPK1KDM4EGAAL3MBTL1MAPT | |
| SCHEMBL638044 | 0.79 | MAPK1 (1.00) | MAPK1KDM4EGAAL3MBTL1MAPT | |
| SCHEMBL638043 | 0.79 | MAPK1 (1.00) | MAPK1KDM4EGAAL3MBTL1MAPT | |
| SCHEMBL18990275 | 0.78 | MAPK1 (0.50) | MAPK1KDM4EGAAL3MBTL1MAPT | |
| SCHEMBL15331425 | 0.78 | MAPK1 (0.76) | MAPK1KDM4EGAAL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187728-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4387974-A1 | COMPOUNDS AS IMMUNOMODULATORS OF PD-L1 INTERACTIONS | Ascletics Bioscience Co., Ltd. (CN) | 2024-06-26 | — | — | EP | disclosed |
| CN-117813309-A | Compounds as immunomodulators for PD-L1 interactions | 歌礼生物科技（杭州）有限公司 | 2024-04-02 | — | — | CN | disclosed |
| US-20230067237-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230067237-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| WO-2023019430-A1 | COMPOUNDS AS IMMUNOMODULATORS OF PD-L1 INTERACTIONS | ASCLETIS BIOSCIENCE CO., LTD. (CN) | 2023-02-23 | — | — | WO | disclosed |
| US-11370792-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-11370792-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-20180370972-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2018-12-27 | — | — | US | disclosed |
| EP-3389664-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | Raze Therapeutics Inc. (US) | 2018-10-24 | — | — | EP | disclosed |
| EP-1091960-A1 | BIFUNCTIONAL ANTAGONISTS OF CYTOKINE-SENSITIVE PROTEIN KINASE ACTIVATION CASCADES AND METHODS FOR USE AS ANTI-INFLAMMATORY AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000061583-A1 | XANTHINE DERIVATIVES AND ANALOGS AS CELL SIGNALING INHIBITORS | CELL THERAPEUTICS, INC. (US) | 2000-10-19 | — | — | WO | disclosed |
| EP-0986561-A1 | COMPOUNDS FOR INHIBITION OF CERAMIDE-MEDIATED SIGNAL TRANSDUCTION | The Regents of the University of California (US) | 2000-03-22 | — | — | EP | disclosed |
| WO-2000000491-A1 | BIFUNCTIONAL ANTAGONISTS OF CYTOKINE-SENSITIVE PROTEIN KINASE ACTIVATION CASCADES AND METHODS FOR USE AS ANTI-INFLAMMATORY AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-01-06 | — | — | WO | disclosed |
| US-5843943-A | Compounds for inhibition of ceramide-mediated signal transduction | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-12-01 | — | — | US | disclosed |
| WO-1998052948-A1 | COMPOUNDS FOR INHIBITION OF CERAMIDE-MEDIATED SIGNAL TRANSDUCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-11-26 | — | — | WO | disclosed |
| EP-0801568-A4 | COMPOUNDS FOR INHIBITION OF CERAMIDE-MEDIATED SIGNAL TRANSDUCTION | UNIV CALIFORNIA (US) | 1998-02-25 | — | — | EP | disclosed |
| EP-0801568-A1 | COMPOUNDS FOR INHIBITION OF CERAMIDE-MEDIATED SIGNAL TRANSDUCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-10-22 | — | — | EP | disclosed |
| EP-0771813-A1 | Alkylxanthine phosphonates and alkylxanthine phosphine oxydes and their use as medicines | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-05-07 | — | — | EP | disclosed |
| WO-1996020710-A1 | COMPOUNDS FOR INHIBITION OF CERAMIDE-MEDIATED SIGNAL TRANSDUCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187728-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | MTHFD2, MTHFD1, NUDT15 | MAPK1 3354/4885KDM4E 1934/4885GAA 592/4885 |
| US-11370792-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | MTHFD2, MTHFD1, NUDT15 | MAPK1 3354/4885KDM4E 1934/4885GAA 592/4885 |
| US-20230067237-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | MTHFD2, MTHFD1, NUDT15 | MAPK1 3354/4885KDM4E 1934/4885GAA 592/4885 |
| US-20180370972-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | MTHFD2, MTHFD1, NUDT15 | MAPK1 3354/4885KDM4E 1934/4885GAA 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.